Visa, an investor in TrialPay's $40m series C round in 2012, is set to buy the company and integrate its marketing platform into its own product offering.

The genomics tool producer has raised more than $100m from investors including General Electric and Myriad Genetics.

The online marketplace paid $267m to buy real estate platform Anjuke, giving an exit to Baidu in the process.

Fosun Pharma-backed Check-Cap has received $12m in an initial public offering and an additional $12m in a private placement.

The cash injection, which is set to be secured at a valuation of up to $40bn, will precede an initial public offering likely to take place in 2017.

The cloud-based authentification service has been bought by Twilio after raising almost $3.8m from backers including Salesforce and Digital Garage.

The Pfizer-backed cancer treatment developer, which initially floated in France in 2007, received $35m from Pfizer last year in return for a 10% stake.

Bristol-Myers Squibb has agreed to buy the cancer specialist just two months after its series B round, in a deal that will involve $800m in cash upfront.

Alzheimer's drug developer Heptares has been acquired by pharmaceutical company Sosei, providing exits to corporate backers Novartis and Takeda.

Seagate-backed customised silicon device maker Easic aims to float on Nasdaq after raising $120m in venture funding.